SynICE™ Bispecific antibody platform

        ADC development platform

        Multi-transmembrane protein antibody development platform

        LaNova Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

        LM-108 Submitted US FDA Clinical Trial Application

        LaNova Medicines Moved to Its New Office at 999 Cailun Road in Zhangjiang Science Park

        LM-102 Obtained China NMPA Clinical Trial Approval

        LM-102 Obtained FDA Clinical Trial Approval and Completed First Patient Dosing

        LM-302 Obtained FDA Clinical Trial Approval

        LM-302 Obtained FDA Orphan Drug Designation

        The Company Successfully Completed Series A Financing